First-line Pembrolizumab Monotherapy
Back to Blog
Mar . 19 . 2019
Kate Boyd
Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first-line pembrolizumab monotherapy in non-clear cell advanced RCC.